COVID-19 vaccines: your questions answered (part 2)

With three COVID-19 vaccines approved in the UK, the focus is now shifting towards how the vaccination programme is being rolled out This podcast picks up where we left off in our previous one, answering a new set of readers questions submitted through the PJ website and social media. Nigel Praities, executive editor, Dawn Connelly, features editor, and Julia Robinson, clinical and science editor, attempt to answer these questions using the latest available information and the help of some external experts. Thanks to Steve Griffin, associate professor in the school of medicine at the University of Leeds, Fazila Jumabhoy, lead pharmacist for Central North Leeds Primary Care Network and John Tregoning, a reader in respiratory disease at Imperial College London. This episode was produced by Geoff Marsh. LINKS Phase 3 trials Pfizer/BioNTech: https://www.nejm.org/doi/full/10.1056/NEJMoa2034577?query=pfw&jwd=000020100690&jspc= Oxford/AstraZeneca: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext Information for healthcare professionals Pfizer/BioNTech: https://www.gov.uk/government/publications/regulatory-approval-of-pfizer-biontech-vaccine-for-covid-19/information-for-healthcare-professionals-on-pfizerbiontech-covid-19-vaccine Oxford/AstraZeneca: https://www.gov.uk/government/publications/regulatory-approval-of-covid-19-vaccine-astrazeneca/information-for-healthcare-professionals-on-covid-19-vaccine-astrazeneca Summary of product characteristics Pfizer/BioNTech: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf